Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-360 dose-finding trial in idiopathic hypersomnia
2024-517712-29-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in hypersomnolence disorder comparing TAK-360 with Placebo (2 arms). Primary endpoint: Occurrence of at least 1 treatment-emergent adverse event. Planned start May 2025; status: authorised.
02
Drugs
TAK-360
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on 2024-517712-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517712-29-00.